Selina M. Luger, M.D., FRCPC

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-615-5888
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Leukemia, myelodysplastic syndrome, myeloproliferative disorders

Description of Clinical Expertise

hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplant

Selected Publications

Lockwood BJ, El-Jawahri A, Walker AR, Ehrman S, Russell D, Kale SS, Gustin J, Bose-Brill S, LeBlanc TW, Luger SM, Lustberg M, Bhatnagar B.: Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. J Adolesc Young Adult Oncol Nov 2022.

Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. Transplant Cell Ther Nov 2022.

Ganzel C, Sun Z, Baslan T, Zhang Y, Gönen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, Litzow M, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E.: Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leuk Res 123: 106971, Oct 2022.

Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad L, Becker PS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E.: An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood Oct 2022.

Aldoss I, Yin J, Wall A, Mrózek K, Liedtke M, Claxton D, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM.: The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study. Blood Adv Oct 2022.

Freyer, C. W., Babushok, D. V., Frey, N. V., Gill, S. I., Loren, A. W., Luger, S. M., Maity, A., Martin, M. E., Plastaras, J. P., Porter, D. L., Hexner, E. O.: Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis. Transplant Cell Ther 28(9): 590-596, Sep 2022.

Freyer, C. W., Carulli, A., Gier, S., Ganetsky, A., Timlin, C., Schuster, M., Babushok, D., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Mangan, J. K., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K., Smith, J., Stadtmauer, E. A., Loren, A. W.: Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. Leuk Lymphoma 63(8): 1925-1933, Aug 2022.

Graveno, M. E., Carulli, A., Freyer, C. W., Mangan, B. L., Nietupski, R., Loren, A. W., Frey, N. V., Porter, D. L., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Babushok, D. V., Pratz, K. W.: Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 63(7): 1645-1650, Jul 2022.

Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., Luger, S. M., Tallman, M. S., Litzow, M. R., Foster, M. C., Erba, H. P., Appelbaum, F. R., Larson, R. A., Keegan, T. H. M., Stock, W.: Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv 6(14): 4085-4092, Jul 2022.

Matthews, A. H., Perl, A. E., Luger, S. M., Loren, A. W., Gill, S. I., Porter, D. L., Babushok, D. V., Maillard, I. P., Carroll, M. P., Frey, N. V., Hexner, E. O., Martin, M. E., McCurdy, S. R., Stadtmauer, E. A., Paralkar, V. R., Bruno, X. J., Hwang, W. T., Margolis, D., Pratz, K. W.: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6(13): 3997-4005, Jul 2022.

back to top
Last updated: 11/23/2022
The Trustees of the University of Pennsylvania